



February 5, 2008

Regeneron Announces Presentation at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Feb. 5, 2008--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Thursday, February 7, 2008. The presentation will provide an overview of the Company and its clinical programs and is scheduled to be broadcast live on Thursday, February 7 at 10:20 a.m. Eastern Time. The session may be accessed through the Company's web site (www.regeneron.com) on the Investor Relations page, under the Presentations heading) at the time of the presentation. An archived version of the presentation will be available after the live webcast through February 21, 2008. Additional information about Regeneron and recent news releases are available on the Regeneron worldwide web site at www.regeneron.com

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.

CONTACT: Regeneron Pharmaceuticals, Inc.
Charles Poole, 914-345-7640
Vice President, Investor Relations
charles.poole@regeneron.com
or
Laura Lindsay, 914-345-7800
Corporate Communications
laura.lindsay@regeneron.com

SOURCE: Regeneron Pharmaceuticals, Inc.